Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety
about
Selective progesterone receptor modulators (SPRMs) for uterine fibroidsCurrent and future medical treatments for menometrorrhagia during the premenopauseEmerging therapy for endometriosisEffect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulationOvarian steroids, stem cells and uterine leiomyoma: therapeutic implications.GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment.Expulsion of a uterine myoma in a patient treated with ulipristal acetate.Progesterone synthesis in the nervous system: implications for myelination and myelin repair.Stro-1/CD44 as putative human myometrial and fibroid stem cell markers.The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up.Safety after extended repeated use of ulipristal acetate for uterine fibroidsTreatment for Uterine Fibroids: Searching for Effective Drug Therapies.Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.A General Method for Nucleophilic Aromatic Substitution of Aryl Fluorides and Chlorides with Dimethylamine using Hydroxide-Assisted Decomposition of N,N-Dimethylforamide.New treatment strategies and emerging drugs in endometriosis.Ulipristal acetate: in uterine fibroids.Ulipristal acetate as an emergency contraceptive agent.Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.Uterine fibroids: clinical manifestations and contemporary management.Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology.Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.Minimising menopausal side effects whilst treating endometriosis and fibroids.Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.Progesterone receptor modulators for endometriosis.The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.Selective progesterone receptor modulators (SPRMs) for uterine fibroids.Pharmacologic treatment of the ovarian endometrioma.Uterine fibroid management: from the present to the future.Genomic and Nongenomic Effects of Mifepristone at the Cardiovascular Level: A Review.Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.Vitamin D(3) enhances ATRA-mediated neurosteroid biosynthesis in human glioma GI-1 cells.BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies.The impact of combined oral contraceptives on ocular tissues: a review of ocular effects.Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Ulipristal acetate for the management of acute heavy menstrual bleeding without fibroids.Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.The Rising Phoenix-Progesterone as the Main Target of the Medical Therapy for Leiomyoma.Selective progesterone receptor modulators: current applications and perspectives.Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.Effect of exposure to ulipristal acetate on sperm function.
P2860
Q24197801-53EBEB91-9A5E-44BD-9075-DD7942C9BC6DQ28255736-FD17EF63-EE54-4945-90C0-8FAC5D86EEC7Q28262987-8F8B83B9-9DDB-479A-A309-23A94CE49B06Q28538130-78528AD4-AE25-4E68-B3D7-8B65A78DA930Q34437666-B63FC863-BA04-4BC6-B297-AD6514350A96Q35063709-3EE75995-60EF-4FD0-A112-D82138540DEDQ35512180-B6E3C2D2-2A3D-4756-93EA-5B313484240FQ35743169-614245DB-9CF9-4C0D-80D9-45B23151684AQ35812468-10683981-3DA7-46F2-ACA6-31B96E84BF19Q35903532-1E55DF6A-D710-4C56-84EC-859DF0C88DB6Q36299562-8B7B8578-7CC2-4E60-B5FE-3C32C1C66066Q36476226-929BF1B0-0049-42AD-890F-8DB843F8F589Q36525065-2B024B33-C3E5-4C42-9FC2-E84883F21722Q37283274-D48E8D28-E645-4C78-BE01-B1E33FE27732Q37996102-04B6D933-C1CC-4673-B79C-86938E6961AAQ38008475-8776E031-7711-411F-A221-AEDFB15B108DQ38024429-7D08FA34-7EAB-44F4-BBA3-0B876AAFFFB6Q38160885-60E26714-5917-4851-BAC1-8ED68108BE45Q38211241-FB824E2B-58CB-41E9-AAB3-88EB416A91D8Q38252992-59524ECF-3353-4753-88D7-DFFB2278147BQ38378813-111F1169-E021-4709-943F-5D6BC1463CE0Q38388553-A9919D75-9027-483C-A080-9D90BAE51E86Q38569796-1D82F8DC-2160-45D1-88A3-0CCF9102D7E1Q38662468-187647A5-C8B6-4284-AE87-5630571BB832Q38676367-8F37B58B-03D0-4BA6-8C37-0382A3C39A39Q38819001-9E5A722C-0DB5-487D-A5B4-E01F2986D843Q38822468-77F3C80A-EA67-405D-8CCA-7520B83CEEE8Q38837038-546DAB2B-5655-4BA2-BF32-676F7CD1CF2DQ38966345-5E2FCDDF-D508-4FD1-A9E4-F5079B268AC3Q38980489-E83165B5-7B27-4B10-938E-F2A612CD296FQ39320096-74DCA37F-51FD-4689-A135-B2D5E5E4DDE7Q45167319-4E29BF77-F812-44D7-BE10-AB5A7E192BE5Q45399966-FE583C3F-7D4E-43E1-8A70-1B0D64B5ECEAQ46560230-ED0C81AD-0558-4E38-B969-317FDCF81098Q47232246-FE13FD61-718D-420D-9778-90B3E31CFA7AQ47282567-FE443199-73E9-4EEF-88FB-0BAABF4AC808Q47561375-37C28603-63A3-43F7-9A1B-E16B191F36E9Q47729672-BB4CA090-8176-4048-9CEC-168A1E55D802Q47773596-A1F1E4A3-DE48-4677-B4EE-CB92A2A04AF6Q51296023-C81FFF46-460B-45D1-8934-05D0E9D4A4B2
P2860
Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Selective progesterone recepto ...... , clinical efficacy and safety
@ast
Selective progesterone recepto ...... , clinical efficacy and safety
@en
Selective progesterone recepto ...... , clinical efficacy and safety
@nl
type
label
Selective progesterone recepto ...... , clinical efficacy and safety
@ast
Selective progesterone recepto ...... , clinical efficacy and safety
@en
Selective progesterone recepto ...... , clinical efficacy and safety
@nl
prefLabel
Selective progesterone recepto ...... , clinical efficacy and safety
@ast
Selective progesterone recepto ...... , clinical efficacy and safety
@en
Selective progesterone recepto ...... , clinical efficacy and safety
@nl
P1476
Selective progesterone recepto ...... , clinical efficacy and safety
@en
P2093
Bart C J M Fauser
Philippe Bouchard
P304
P356
10.1016/J.FERTNSTERT.2011.08.021
P407
P577
2011-11-01T00:00:00Z